News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Phase 3 data expected in the second half of 2024
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Subscribe To Our Newsletter & Stay Updated
